Our sister site, Drug Delivery Business News, reports today that the FDA cleared the medtech giant’s new InPen insulin delivery system application. Clearance paves the way for the launch of the company’s smart multiple daily injection (MDI) system. That system includes the recently FDA-cleared next-generation Simplera continuous glucose monitor (CGM).
Clearance makes the smart MDI system the first on the market to recommend corrections for missed or inaccurate insulin doses, according to a news release. It provides real-time, personalized insights for individuals on MDI therapy. Medtronic says its smart MDI system reduces the guesswork of diabetes management. It helps address an unmet need for MDI users who struggle with juggling numerous decisions around insulin dosing on a daily basis.
Get the full story at our sister site, Drug Delivery Business News.
